supplementation with EPA and DHA in infancy may result in increased quality of life, as well as decreased health care costs, for those afflicted with allergic conditions
Fort Lauderdale, FL (PRWEB) July 30, 2012
While the incidence, as well as prevalence, of allergic disorders in the developing world continues to rise, a new study, published in the journal Clinical and Experimental Allergy, adds weight to the immune bolstering properties of omega-3 fatty acids, such as found in Omega XL®.
According to the study, a double-blind randomized controlled trial with 420 infants, increased blood levels of supplemented omega3s, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), demonstrated a decreased allergic response to certain allergens in the infants given omega-3s. According to the researchers from the University of Western Australia, “To our knowledge, this is the first study to examine the effects of direct postnatal fish oil supplementation on immune development in the first 6 months of life.”
These findings are in agreement with growing evidence that optimizing omega-3 fatty acids during early life may have a favorable effect on immunity and allergy development.
Blood data from 420 infants, 120 given a daily dose of 280 mg of DHA and 110 mg of EPA, the remaining a placebo, from birth to six months of age, was analyzed. Results showed that EPA and DHA were significantly higher in the omega-3 group. This group demonstrated lower allergic responses to dust mites and milk protein, as well as significantly lower allergen specific responses associated with symptoms of eczema at 6 months of age and diagnosed eczema at 12 months of age.
These results demonstrated the allergy protecting properties of EPA and DHA, suggesting that the simple step of supplementation with EPA and DHA in infancy may result in increased quality of life, as well as decreased health care costs, for those afflicted with allergic conditions.
Omega XL is one of only two Omega 3 supplements sold in the world that contains the patented stabilized marine lipid extract PCSO-524™ derived only from the New Zealand green-lipped mussel, with 30 healthy fatty acids including DHA and EPA. Sold in other parts of the world under its sister brand name Lyprinol, Omega XL is manufactured exclusively by Great HealthWorks Inc., and is the most widely available omega-3 fish oil supplement containing the potent PCSO-524™ marine lipid extract. To find more information about Omega XL and PCSO-524™ visit http://www.OmegaXL.com
Source: Clinical and Experimental Allergy
Volume 42, Number 8, Pages 12061216, doi: 10.1111/j.13652222.2012.04031.x
“Fish oil supplementation in early infancy modulates developing infant immune responses” 7/23/12 Omega 3s may protect children against allergies
About Great HealthWorks, Inc.
Great HealthWorks, founded in 2003, is a global manufacturer and distributor of one-of-a-kind, natural products. Great HealthWorks, the makers of Omega XL®, an all-natural, highly purified marine lipid extract from the green-lipped mussel (Perna Canaliculus) known as PCSO-524™. This patented marine lipid complex comes exclusively from the pristine waters of the Marlborough Sounds in New Zealand, and contains 30 healthy fatty acids. Great HealthWorks corporate headquarters and distribution center are in Hollywood, Florida. To find out more about Great HealthWorks, visit http://www.GreatHealthWorks.com. And for more information about the benefits of Omega XL, visit http://www.OmegaXL.com. Join the conversation: http://www.facebook.com/myomegaxl